{"disease":{"id":"genetic-diseases-inborn","name":"genetic diseases inborn"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03627767","title":"Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1235,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03720470","title":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":838,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03738098","title":"NYCKidSeq: Incorporating Genomics Into Clinical Care of Diverse NYC Children","phase":"NA","overall_status":"COMPLETED","enrollment_count":650,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT03179631","title":"Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":360,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT03342495","title":"Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":337,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT03054428","title":"Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":true},{"nct_id":"NCT05290701","title":"Evaluating Prenatal Exome Sequencing Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":235,"lead_sponsor_name":"Leiden University Medical Center","has_results":false},{"nct_id":"NCT01826487","title":"Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":230,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT02090959","title":"An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":219,"lead_sponsor_name":"PTC Therapeutics","has_results":true},{"nct_id":"NCT04208529","title":"A Long-term Follow-up Study in Participants Who Received CTX001","phase":"PHASE3","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":160,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT05070234","title":"Genetic Diagnosis and Human Growth Hormone Treatment in Small for Gestational Age Children With Short Stature","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Chunxiu Gong","has_results":false},{"nct_id":"NCT03655678","title":"A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT05479981","title":"Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false},{"nct_id":"NCT05477563","title":"Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":26,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT03876301","title":"Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03563066","title":"Effect of Benralizumab in Atopic Dermatitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"McMaster University","has_results":true},{"nct_id":"NCT03406780","title":"A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Capricor Inc.","has_results":true},{"nct_id":"NCT05356195","title":"Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":16,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false},{"nct_id":"NCT05730842","title":"Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Edgewise Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05657860","title":"Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Maimonides Medical Center","has_results":false},{"nct_id":"NCT03718234","title":"Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"University of Minnesota","has_results":true},{"nct_id":"NCT03734588","title":"Dose-finding Study of SPK-8016 Gene Therapy in Patients With Hemophilia A to Support Evaluation in Individuals With FVIII Inhibitors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Spark Therapeutics, Inc.","has_results":true},{"nct_id":"NCT03721458","title":"Whole Genome Sequencing in the Neonatal Intensive Care Unit","phase":"","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Milton S. Hershey Medical Center","has_results":false},{"nct_id":"NCT01963650","title":"Natural History Study of Children With Metachromatic Leukodystrophy","phase":"","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Shire","has_results":false},{"nct_id":"NCT07250737","title":"Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Avidity Biosciences, Inc.","has_results":false}],"total":25},"guidelines":[],"source":"Drug Landscape verified database"}